Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

Rothschedl E
Record ID 32018000339
Authors' results and conclusions: SOLO1 trial results showed a benefit with olaparib first-line maintenance therapy in delaying the disease progression in patients with newly diagnosed ovarian cancer and BRCA1/2 mutation. However, the trial is currently ongoing, the presented data are the primary analysis data, and interim overall survival (OS) data are immature. Health-related quality of life data also derives from primary analysis and the detected between-group difference was not considered to be clinically meaningful. Final analysis data from the SOLO1 trial is pending and may confirm the clinical benefit of olaparib first-line maintenance therapy.
Authors' recomendations: Further investigation of olaparib first-line maintenance therapy in phase III trials, long-term data, as well as a direct comparison of olaparib with different poly (ADP-ribose) polymerase (PARP) inhibitors are warranted to determine the optimal treatment for this patient population.
Project Status: Completed
Year Published: 2019
URL for additional information: http://eprints.aihta.at/1192/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Therapeutics
  • Pharmacology
  • Ovarian Neoplasms
  • Antineoplastic Agents
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Progression-Free Survival
  • Olaparib
  • Lynparza┬«
  • ovarian cancer
  • first-line therapy
  • PARP inhibitor
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.